Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 3/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842874 | 1.00 | LGALS8 (0.47) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL16148734 | 0.91 | LGALS8 (0.51) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL16148735 | 0.91 | LGALS8 (0.51) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL24155775 | 0.89 | LGALS8 (0.53) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL469613 | 0.89 | LGALS8 (0.53) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL19772749 | 0.89 | LGALS8 (0.53) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL20306671 | 0.86 | LGALS8 (0.49) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL17867787 | 0.83 | MAPK1 (0.45) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL17867785 | 0.83 | MAPK1 (0.45) | LGALS8LGALS3LGALS4MAPK1GBA1 | |
| SCHEMBL17087897 | 0.83 | LGALS8 (0.56) | LGALS8LGALS3LGALS4MAPK1GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318423-B1 | PROCESS FOR MAKING 5-AZACYTOSINE NUCLEOSIDES AND THEIR DERIVATIVES | SCINOPHARM TAIWAN LTD (TW) | 2014-05-07 | — | — | EP | disclosed |
| US-8212021-B2 | Process for making 5-azacytosine nucleosides and their derivatives | SCINOPHARM TAIWAN, LTD. (TW) | 2012-07-03 | — | — | US | disclosed |
| US-20100036112-A1 | Process for Making 5-Azacytosine Nucleosides and Their Derivatives | SCINOPHARM TAIWAN LTD. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036112-A1 | Process for Making 5-Azacytosine Nucleosides and Their Derivatives | DCTD, DUT, DPYD | LGALS8 1977/4885LGALS3 2641/4885LGALS4 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.